Version in force 1 March 2022

Previous version, in force 1 October 2021 02008R1272-20211001 → this version, in force 1 March 2022 02008R1272-20220301

compared line by line: this provision is too large to compare word by word, so a marked line is a line that changed somewhere

ANNEX VI Harmonised classification and labelling for certain hazardous substances Part 1 of this Annex provides an introduction to the list of harmonised classification and labelling, including information listed for each entry and related classifications and hazard statements in Table 3. … 1,819 unchanged lines … Acute Tox. 4 * H312 H302 GHS07 Wng H312 H302 007-004-00-1 nitric acid … % 231-714-2 7697-37-2 Ox. Liq. 2 H302 007-004-00-1 nitric acid …% [C > 70 %] 231-714-2 7697-37-2 Ox. Liq. 2 Acute Tox. 1 Skin Corr. 1A H272 H330 H314 GHS03 GHS06 GHS05 Dgr H272 H314 EUH071 Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 99 % > C ≥ 65 % B H330 H314 EUH071 Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 70 % ≤ C < 99 % B 007-006-00-2 ethyl nitrite 203-722-6 109-95-5 Flam. Gas 1 Press. Gas Acute Tox. 4 * … 315 unchanged lines … GHS07 Dgr H312 H302 H314 008-001-00-8 oxygen 231-956-9 7782-44-7 Ox. Gas 1 H314 007-030-00-3 nitric acid …% [C ≤ 70 %] 231-714-2 7697-37-2. Ox. Liq. 3 Acute Tox. 3 Skin Corr. 1A H272 H331 H314 GHS03 GHS06 GHS05 Dgr H272 H331 H314 EUH071 Ox. Liq. 3; H272: C ≥ 65 % inhalation: ATE = 2,65 mg/L (vapours) Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % B 008-001-00-8 oxygen 231-956-9 7782-44-7 Ox. Gas 1 Press. Gas H270 GHS03 GHS04 Dgr H270 U … 407 unchanged lines … GHS09 Dgr H351 H360D *** H302 H411 014-018-00-1 octamethylcyclotetrasiloxane 209-136-7 556-67-2 Repr. 2 Aquatic Chronic 4 H361f *** H413 GHS08 Wng H361f *** H413 014-019-00-7 reaction mass of: 4-[[bis-(4-fluorophenyl)methylsilyl]methyl]-4H-1,2,4-triazole; H411 014-018-00-1 octamethylcyclotetrasiloxane; [D4] 209-136-7 556-67-2 Repr. 2 Aquatic Chronic 1 H361f *** H410 GHS08 GHS09 Wng H361f *** H410 M = 10 014-019-00-7 reaction mass of: 4-[[bis-(4-fluorophenyl)methylsilyl]methyl]-4H-1,2,4-triazole; 1-[[bis-(4-fluorophenyl)methylsilyl]methyl]-1H-1,2,4-triazole 403-250-2 — Carc. 2 Repr. 1B Acute Tox. 4 * … 129 unchanged lines … Dgr H350i A 014-047-00-X glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] — — Carc. 2 H351 (inhalation) GHS08 Wng H351 (inhalation) A 015-001-00-1 white phosphorus 231-768-7 12185-10-3 Pyr. Sol. 1 014-048-00-5 silicon carbide fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1) 206-991-8 409-21-2 308076-74-6 Carc. 1B H350i GHS08 Dgr H350i 014-049-00-0 trimethoxyvinylsilane; trimethoxy(vinyl)silane 220-449-8 2768-02-7 Skin Sens. 1B H317 GHS07 Wng H317 014-050-00-6 tris(2-methoxyethoxy)vinylsilane; 6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane 213-934-0 1067-53-4 Repr. 1B H360FD GHS08 Dgr H360FD 015-001-00-1 white phosphorus 231-768-7 12185-10-3 Pyr. Sol. 1 Acute Tox. 2 * Acute Tox. 2 * Skin Corr. 1A … 1,288 unchanged lines … GHS09 Wng H302 H410 M = 10 015-134-00-5 pirimiphos-methyl (ISO); O-(2-diethylamino-6-methylpyrimidin-4-yl) O, O-dimethyl phosphorothioate 249-528-5 29232-93-7 Acute Tox. 4 * O-[2-(diethylamino)-6-methylpyrimidin-4-yl] O,O-dimethyl phosphorothioate 249-528-5 29232-93-7 Acute Tox. 4 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H302 H372 (nervous system) H400 H410 GHS07 GHS08 GHS09 Wng H302 H410 015-135-00-0 profenofos (ISO)O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl phosphorothioate; 255-255-2 41198-08-7 Acute Tox. 4 * Dgr H302 H372 (nervous system) H410 oral: ATE = 1414 mg/kg bw M = 1000 M = 1000 015-135-00-0 profenofos (ISO)O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl phosphorothioate; 255-255-2 41198-08-7 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 … 395 unchanged lines … H317 H412 015-181-00-1 phosphine 232-260-8 7803-51-2 Flam. Gas 1 Press. Gas Acute Tox. 2 * Acute Tox. 1 Skin Corr. 1B Aquatic Acute 1 H220 H330 H314 H400 GHS02 GHS04 GHS06 GHS05 GHS09 Dgr H220 H330 H314 H400 U H400 inhalation: ATE = 10 ppmV (gases) U 015-182-00-7 tetrapropan-2-yl (dichloromethanediyl)bis(phosphonate) 430-630-5 10596-22-2 Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 H302 … 752 unchanged lines … Dgr H302 H314 H317 H412 017-001-00-7 chlorine 231-959-5 7782-50-5 Ox. Gas 1 H412 016-098-00-3 dimethyl disulphide 210-871-0 624-92-0 Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 STOT SE 3 STOT SE 1 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H400 H410 GHS02 GHS06 GHS08 GHS09 Dgr H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H410 inhalation: ATE = 5 mg/L (vapours) oral: ATE = 190 mg/kg bw M = 1 M = 10 017-001-00-7 chlorine 231-959-5 7782-50-5 Ox. Gas 1 Press. Gas Acute Tox. 3 * Eye Irrit. 2 … 2,369 unchanged lines … GHS09 Dgr H302 H318 H410 M = 10 030-001-00-1 zinc powder — zinc dust (pyrophoric) 231-175-3 7440-66-6 Water-react. 1 H410 M = 10 029-024-00-X granulated copper; [particle length: from 0,9 mm to 6,0 mm; particle width: from 0,494 to 0,949 mm] 231-159-6 7440-50-8 Aquatic Chronic 2 H411 GHS09 H411 029-025-00-5 bis(N-hydroxy-N-nitrosocyclohexylaminato-O,O’)copper; bis(N-cyclohexyl-diazenium-dioxy)-copper; [Cu-HDO] 239-703-4 312600-89-8 15627-09-5 Flam. Sol. 1 Acute Tox. 4 STOT RE 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H228 H302 H373 (liver) H318 H400 H410 GHS02 GHS07 GHS08 GHS05 GHS09 Dgr H228 H302 H373(liver) H318 H410 oral: ATE = 360 mg/kg bw M = 1 M = 1 030-001-00-1 zinc powder — zinc dust (pyrophoric) 231-175-3 7440-66-6 Water-react. 1 Pyr. Sol. 1 Aquatic Acute 1 Aquatic Chronic 1 H260 … 948 unchanged lines … H413 GHS08 GHS07 Dgr H372 ** H315 H413 050-021-00-4 dichlorodioctyl stannane 222-583-2 3542-36-7 Acute Tox. 3 * H413 050-021-00-4 dichlorodioctylstannane 222-583-2 3542-36-7 Repr. 1B Acute Tox. 2 STOT RE 1 Aquatic Chronic 3 H331 H372** H412 GHS06 GHS08 Dgr H331 H372** H412 050-022-00-X dibutyltin dichloride; Aquatic Chronic 3 H360D H330 H372 ** H412 GHS08 GHS06 Dgr H360D H330 H372 ** H412 Repr. 1B; H360 D: C ≥ 0,03 % inhalation: ATE = 0,098 mg/L (dusts or mists) 050-022-00-X dibutyltin dichloride; (DBTC) 211-670-0 683-18-1 Muta. 2 Repr. 1B Acute Tox. 2 * … 56 unchanged lines … H317 H410 050-025-00-6 trichloromethylstannane 213-608-8 993-16-8 Repr. 2 H361d GHS08 Wng H361d 050-026-00-1 2-ethylhexyl 10-ethyl-4-[[2-[(2-ethylhexyl)oxy]-2-oxoethyl]thio]-4-methyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate 260-828-5 57583-34-3 Repr. 2 H361d GHS08 Wng H361d 050-027-00-7 2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate 239-622-4 15571-58-1 Repr. 1B H360D GHS08 Dgr H360D 050-028-00-2 2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate 260-829-0 57583-35-4 Repr. 2 Wng H361d 050-027-00-7 2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE] 239-622-4 15571-58-1 Repr. 1B STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H372 (immune system) H400 H410 GHS08 GHS09 Dgr H360D H372 (immune system) H410 050-028-00-2 2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate 260-829-0 57583-35-4 Repr. 2 Acute Tox. 4 STOT RE 1 Skin Sens. 1A H361d … 31 unchanged lines … H372 (immune system) GHS08 Dgr H341 H360FD H372 (immune system) 050-031-00-9 dioctyltin dilaurate; [1] stannane, dioctyl-, bis(coco acyloxy) derivs. [2] 222-883-3 [1] 293-901-5 [2] 3648-18-8 [1] 91648-39-4 [2] Repr. 1B STOT RE 1 H360D H372 (immune system) GHS08 Dgr H360D H372 (immune system) 051-001-00-8 antimony trichloride 233-047-2 10025-91-9 Skin Corr. 1B Aquatic Chronic 2 H314 H411 GHS05 … 769 unchanged lines … GHS09 Wng H302 H373** H411 082-013-00-1 lead powder; [particle diameter < 1 mm] 231-100-4 7439-92-1 Repr. 1A Lact. H360FD H362 GHS08 Dgr H360FD H362 Repr. 1A; H360D: C ≥ 0,03 % 082-014-00-7 lead massive: H411 082-013-00-1 lead powder; [particle diameter < 1 mm] 231-100-4 7439-92-1 Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1 H360FD H362 H400 H410 GHS08 GHS09 Dgr H360FD H362 H410 Repr. 1A; H360D: C ≥ 0,03 % M = 1 M = 10 082-014-00-7 lead massive: [particle diameter ≥ 1 mm] 231-100-4 7439-92-1 Repr. 1A Lact. H360FD H362 GHS08 … 945 unchanged lines … Muta. 2 H350 H341 GHS08 Dgr H350 H341 602-001-00-7 chloromethane; H341 601-092-00-0 dibenzo[def,p]chrysene; dibenzo[a,l]pyrene 205-886-4 191-30-0 Carc. 1B Muta. 2 H350 H341 GHS08 Dgr H350 H341 Carc. 1B; H350: C ≥ 0,001 % 602-001-00-7 chloromethane; methyl chloride 200-817-4 74-87-3 Flam. Gas 1 Press. Gas Carc. 2 … 1,458 unchanged lines … Wng H332 H312 H319 603-014-00-0 2-butoxyethanol; ethyleneglycol monobutyl ether; butyl cellosolve 203-905-0 111-76-2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 H332 H312 ethylene glycol monobutyl ether 203-905-0 111-76-2 Acute Tox. 4* Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 H332 H302 H319 H315 GHS07 H315 H319 GHS07 Wng H332 H312 H302 H319 H315 603-015-00-6 allyl alcohol 203-470-7 107-18-6 Flam. Liq. 2 H315 H319 oral: ATE = 1200 mg/kg bw 603-015-00-6 allyl alcohol 203-470-7 107-18-6 Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * … 564 unchanged lines … H336 GHS02 GHS07 Wng H226 H336 603-065-00-9 resorcinol diglycidyl ether;1,3-bis(2,3-epoxypropoxy)benzene 202-987-5 101-90-6 Carc. 2 H336 603-065-00-9 m-bis(2,3-epoxypropoxy)benzene; resorcinol diglycidyl ether 202-987-5 101-90-6 Carc. 1B Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 H351 Aquatic Chronic 3 H350 H341 H312 H311 H302 H315 H319 H315 H317 H412 GHS08 GHS07 Wng H351 GHS06 Dgr H350 H341 H312 H311 H302 H315 H319 H315 H317 H412 603-066-00-4 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide 203-437-7 106-87-6 Carc. 2 H412 dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw 603-066-00-4 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide 203-437-7 106-87-6 Carc. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * H351 H331 … 992 unchanged lines … 126-90-9 [2] 126-91-0 [3] Skin Sens. 1B H317 GHS07 Wng H317 603-236-00-8 ethanol, 2,2’-iminobis-, N-(C13-15-branched and linear alkyl) derivs. 308-208-6 97925-95-6 Repr. 1B H360D GHS08 Dgr H360D 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2 Dgr H360D 603-237-00-3 ipconazole (ISO); (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol - 125225-28-7 115850-69-6 115937-89-8 Repr. 1B Acute Tox. 4 STOT RE 2 Aquatic Chronic 1 H360D H302 H373 (eyes, skin, liver) H410 GHS08 GHS07 GHS09 Dgr H360D H302 H373 (eyes, skin, liver) H410 oral: ATE = 500 mg/kg bw M = 100 603-238-00-9 bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme 205-594-7 143-24-8 Repr. 1B H360FD GHS08 Dgr H360FD 603-239-00-4 paclobutrazol (ISO); (2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol - 76738-62-0 Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H361d H332 H302 H319 H400 H410 GHS08 GHS07 GHS09 Wng H361d H332 H302 H319 H410 inhalation: ATE = 3,13 mg/L (dusts or mists) oral: ATE = 490 mg/kg bw M = 10 M = 10 603-240-00-X 2,2-bis(bromomethyl)propane-1,3-diol 221-967-7 3296-90-0 Carc. 1B Muta. 1B H350 H340 GHS08 Dgr H350 H340 603-241-00-5 geraniol; (2E)-3,7-dimethylocta-2,6-dien-1-ol 203-377-1 106-24-1 Skin Sens. 1 H317 GHS07 Wng H317 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Skin Corr. 1B H341 … 1,135 unchanged lines … 257-187-9 [3] 130066-44-3 [1] 31906-04-4 [2] 51414-25-6 [3] Skin Sens. 1A H317 GHS07 Wng H317 606-001-00-8 acetone; propan-2-one; propanone 200-662-2 67-64-1 Flam. Liq. 2 Wng H317 605-041-00-3 2-(4-tert-butylbenzyl)propionaldehyde 201-289-8 80-54-6 Repr. 1B H360Fd GHS08 Dgr H360Fd 606-001-00-8 acetone; propan-2-one; propanone 200-662-2 67-64-1 Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 H225 H319 … 2,415 unchanged lines … H411 GHS07 GHS09 Wng H317 H411 607-177-00-9 tribenuron-methyl (ISO); 2-[4-methoxy-6-methyl-1,3,5-triazin-2-yl(methyl)carbamoylsulfamoyl]benzoic acid methyl ester; methyl 2-(3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-3methylureidosulfonyl)benzoate 401-190-1 101200-48-0 Skin Sens. 1 H411 607-177-00-9 tribenuron-methyl (ISO); methyl 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylcarbamoylsulfamoyl]benzoate 401-190-1 101200-48-0 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 Aquatic Chronic 1 H373 H317 H400 H410 GHS07 H410 GHS08 GHS07 GHS09 Wng H317 H410 M = 100 607-178-00-4 methyl α-((4,6-dimethoxypyrimidin-2-yl)ureidosulphonyl)-o-toluate 401-340-6 83055-99-6 Skin Sens. 1 Wng H373 H317 H410 M = 100 M = 100 607-178-00-4 methyl α-((4,6-dimethoxypyrimidin-2-yl)ureidosulphonyl)-o-toluate 401-340-6 83055-99-6 Skin Sens. 1 Aquatic Chronic 2 H317 H411 GHS07 GHS09 … 535 unchanged lines … GHS09 Dgr H330 H300 H410 607-255-00-2 fluroxypyr (ISO);4-amino-3,5-dichloro-6-fluoro-2-pyridyloxyacetic acid — 69377-81-7 Aquatic Chronic 3 H412 — H412 607-256-00-8 azoxystrobin (ISO); methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate — 131860-33-8 Acute Tox. 3 * Aquatic Acute 1 H410 607-255-00-2 fluroxypyr (ISO);4-amino-3,5-dichloro-6-fluoro-2-pyridyloxyacetic acid — 69377-81-7 Aquatic Chronic 3 H412 — H412 607-256-00-8 azoxystrobin (ISO); methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate - 131860-33-8 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 H331 H400 H410 GHS06 GHS09 Dgr H331 H410 607-257-00-3 isopropyl propionate 211-300-8 637-78-5 Flam. Liq. 2 H225 GHS02 H410 inhalation: ATE = 0,7 mg/L (dusts or mists) M = 10 M = 10 607-257-00-3 isopropyl propionate 211-300-8 637-78-5 Flam. Liq. 2 H225 GHS02 Dgr H225 607-258-00-9 dodecyl 3-(2-(3-benzyl-4-ethoxy-2,5-dioxoimidazolidin-1-yl)-3-(4-methoxybenzoyl)acetamido)-4-chlorobenzoate 403-990-6 70950-45-7 Aquatic Chronic 4 H413 — H413 607-259-00-4 methyl 2R,3S-(-)-3-(4-methoxyphenyl)oxiranecarboxylate 404-130-2 105560-93-8 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 H318 … 262 unchanged lines … GHS06 Dgr H330 H302 H314 STOT SE 3; H335: C ≥ 5 % 607-314-00-2 ethofumesate (ISO); (±)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-ylmethanesulfonate 247-525-3 26225-79-6 Aquatic Chronic 2 H411 GHS09 H411 607-315-00-8 glyphosate (ISO); N-(phosphonomethyl)glycine 213-997-4 1071-83-6 Eye Dam. 1 H314 STOT SE 3; H335: C ≥ 5 % 607-314-00-2 ethofumesate (ISO); (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate 247-525-3 26225-79-6 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 1 607-315-00-8 glyphosate (ISO); N-(phosphonomethyl)glycine 213-997-4 1071-83-6 Eye Dam. 1 Aquatic Chronic 2 H318 H411 GHS05 GHS09 … 2,160 unchanged lines … Wng H332 H373 (inhalation) inhalation: ATE = 1,5 mg/l (dusts or mists) 607-737-00-2 diisohexyl phthalate 276-090-2 71850-09-4 Repr. 1B H360FD GHS08 Dgr H360FD 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 Dgr H360FD 607-738-00-8 MCPA-thioethyl (ISO); S-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro-o-tolyloxythioacetate 246-831-4 25319-90-8 Acute Tox. 4 STOT RE. 2 Aquatic Acute 1 Aquatic Chronic 1 H302 H373 (liver) H400 H410 GHS07 GHS08 GHS09 Wng H302 H373 (liver) H410 oral: ATE = 450 mg/kg bw M = 10 M = 10 607-740-00-9 diisooctyl phthalate 248-523-5 27554-26-3 Repr. 1B H360FD GHS08 Dgr H360FD 607-741-00-4 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one; flupyradifurone — 951659-40-8 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H302 H373 (muscle) H400 H410 GHS07 GHS08 GHS09 Wng H302 H373 (muscle) H410 oral: ATE = 500 mg/kg bw M = 10 M = 10 607-742-00-X thiencarbazone-methyl (ISO); methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophene-3-carboxylate — 317815-83-1 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1000 M = 1000 607-743-00-5 L-(+)-lactic acid; (2S)-2-hydroxypropanoic acid 201-196-2 79-33-4 Skin Corr. 1C Eye Dam. 1 H314 H318 GHS05 Dgr H314 EUH071 607-744-00-0 2-methoxyethyl acrylate 221-499-3 3121-61-7 Flam. Liq. 3 Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1 H226 H341 H360FD H331 H302 H314 H318 H317 GHS02 GHS05 GHS06 GHS08 Dgr H226 H341 H360FD H331 H302 H314 H317 EUH071 inhalation: ATE = 2,7 mg/L (vapours) oral: ATE = 404 mg/kg bw 607-745-00-6 glyoxylic acid …% 206-058-5 298-12-4 Eye Dam. 1 Skin Sens. 1B H318 H317 GHS05 GHS07 Dgr H318 H317 B 607-746-00-1 sodium N-(hydroxymethyl)glycinate; [formaldehyde released from sodium N-(hydroxymethyl)glycinate] 274-357-8 70161-44-3 Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 H350 H341 H332 H302 H335 H315 H319 H317 GHS08 GHS07 Dgr H350 H341 H332 H302 H335 H315 H319 H317 inhalation: ATE = 3 mg/L (dusts or mists) oral: ATE = 1100 mg/kg bw 8 9 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 H225 H332 … 1,097 unchanged lines … Dgr H350 H360D *** H302 H410 609-041-00-4 2,4-dinitrophenol 200-087-7 51-28-5 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Acute 1 H331 H311 H301 H373 ** H300 H372 H400 GHS06 GHS08 GHS09 Dgr H331 H311 H301 H373 ** H400 609-042-00-X pendimethalin (ISO); H300 H372 H400 dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw 609-042-00-X pendimethalin (ISO); N-(1-ethylpropyl)-2,6-dinitro-3,4-xylidine 254-938-2 40487-42-1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 … 314 unchanged lines … H411 GHS07 GHS09 Wng H302 H411 609-064-00-X mesotrione(ISO); 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione — 104206-82-8 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 609-065-00-5 2-nitrotoluene 201-853-3 88-72-2 Carc. 1B H411 609-064-00-X mesotrione (ISO); 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione - 104206-82-8 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361d H373 (eyes, nervous system) H400 H410 GHS08 GHS09 Wng H361d H373 (eyes, nervous system) H410 M = 10 M = 10 609-065-00-5 2-nitrotoluene 201-853-3 88-72-2 Carc. 1B Muta. 1B Repr. 2 Acute Tox. 4 * … 1,071 unchanged lines … GHS07 Dgr H318 H317 611-180-00-0 iron, complexes with diazotised 4-aminobenzenesulfonamide, diazotized 3-aminobenzenesulfonic acid, diazotised 3-amino-4-hydroxybenzenesulfonamide, diazotised 3-amino-4-hydroxy-N-phenylbenzenesulfonamide, diazotised 5-amino-2-(phenylamino)benzenesulfonic acid and resorcinol, sodium salts 417-850-7 — Aquatic Chronic 2 H411 GHS09 H411 612-001-00-9 mono-methylamine; [1] 4-aminobenzenesulfonamide, diazotized 3-aminobenzenesulfonic acid, diazotised 3-amino-4-hydroxybenzenesulfonamide, diazotised 3-amino-4-hydroxy-N-phenylbenzenesulfonamide, diazotised 5-amino-2-(phenylamino)benzenesulfonic acid and resorcinol, sodium salts 417-850-7 — Aquatic Chronic 2 H411 GHS09 H411 611-181-00-6 potassium (oxido-NNO-azoxy)cyclohexane; cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO] - 66603-10-9 Flam. Sol. 1 Acute Tox. 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 H228 H301 H373 (liver) H315 H318 H411 GHS02 GHS06 GHS08 GHS05 GHS09 Dgr H228 H301 H373 (liver) H315 H318 H411 oral: ATE = 136 mg/kg bw 612-001-00-9 mono-methylamine; [1] di-methylamine; [2] tri-methylamine [3] 200-820-0 [1] 204-697-4 [2] … 3,542 unchanged lines … GHS05 Dgr H361f H302 H314 EUH071 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2 H314 EUH071 612-294-00-3 mecetronium etilsulfate; N-ethyl-N,N-dimethylhexadecan-1-aminium ethyl sulfate; mecetronium ethyl sulphate; [MES] 221-106-5 3006-10-8 Skin Corr. 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H314 H318 H400 H410 GHS05 GHS09 Dgr H314 H410 EUH071 M = 100 M = 1000 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2 Carc. 1B Muta. 1B Acute Tox. 2 * … 1,044 unchanged lines … H319 GHS08 GHS07 Wng H361d *** H302 H319 613-112-00-5 octhilinone (ISO);2-octyl-2H-isothiazol-3-one 247-761-7 26530-20-1 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H331 H319 613-112-00-5 octhilinone (ISO); 2-octyl-2H-isothiazol-3-one; [OIT] 247-761-7 26530-20-1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H330 H311 H302 H301 H314 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H331 Dgr H330 H311 H302 H301 H314 H317 H410 Skin Sens. 1; H317: C≥0,05 % 613-113-00-0 2-(morpholinothio)benzothiazole 203-052-4 102-77-2 Eye Irrit. 2 H410 EUH071 inhalation: ATE = 0,27 mg/L (dusts or mists) dermal: ATE = 311 mg/kg bw oral: ATE = 125 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100 613-113-00-0 2-(morpholinothio)benzothiazole 203-052-4 102-77-2 Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 H319 H315 H317 H411 GHS07 GHS09 Wng H319 H315 H317 H411 613-114-00-6 2,2',2''-(hexahydro-1,3,5- triazine-1,3,5-triyl)triethanol;1,3,5-tris(2-hydroxyethyl)hexahydro-1,3,5-triazine 225-208-0 4719-04-4 Acute Tox. 4 * Skin Sens. 1 H302 H317 GHS07 Wng H302 H317 Skin Sens. 1; H317: C ≥ 0,1 % 613-115-00-1 hymexazol (ISO);3-hydroxy-5-methylisoxazole 233-000-6 10004-44-1 Acute Tox. 4 * 0,1 % 613-115-00-1 hymexazol (ISO); 3-hydroxy-5-methylisoxazole 233-000-6 10004-44-1 Repr. 2 Acute Tox. 4 Eye Dam. 1 Aquatic Chronic 3 H302 Skin Sens. 1 Aquatic Chronic 2 H361d H302 H318 H412 GHS05 H317 H411 GHS08 GHS07 Dgr H302 GHS05 GHS09 Dgr H361d H302 H318 H412 613-116-00-7 tolylfluanid (ISO);dichloro-N-[(dimethylamino)sulphonyl]fluoro-N-(p-tolyl)methanesulphenamide;[containing ≥0.1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] 211-986-9 731-27-1 Acute Tox. 2 * STOT RE 1 H317 H411 oral: ATE = 1600 mg/kg bw 613-116-00-7 tolylfluanid (ISO);dichloro-N-[(dimethylamino)sulphonyl]fluoro-N-(p-tolyl)methanesulphenamide;[containing ≥0.1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] 211-986-9 731-27-1 Acute Tox. 2 * STOT RE 1 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 … 83 unchanged lines … GHS09 Wng H361d *** H302 H315 H411 613-125-00-6 hexythiazox(ISO);trans-5-(4-chlorophenyl)-N- cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide — 78587-05-0 Aquatic Acute 1 H411 613-125-00-6 hexythiazox (ISO); trans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide - 78587-05-0 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 613-126-00-1 imazapyr (ISO);2-[4,5-dihydro-4-methyl-4-(1- methylethyl)-5-oxo-1H- imidazol-2-yl]-3-pyridine carboxylate — 81334-34-1 Eye Irrit. 2 Wng H410 M = 1 M = 1 613-126-00-1 imazapyr (ISO);2-[4,5-dihydro-4-methyl-4-(1- methylethyl)-5-oxo-1H- imidazol-2-yl]-3-pyridine carboxylate — 81334-34-1 Eye Irrit. 2 Aquatic Chronic 3 H319 H412 GHS07 Wng H319 … 544 unchanged lines … H302 H317 H410 EUH070 613-202-00-4 pymetrozine (ISO); (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one — 123312-89-0 Carc. 2 Aquatic Chronic 3 H351 H412 GHS08 (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one - 123312-89-0 Carc. 2 Repr. 2 Aquatic Chronic 1 H351 H361fd H410 GHS08 GHS09 Wng H351 H412 613-203-00-X pyraflufen-ethyl (ISO); H361fd H410 M = 1 613-203-00-X pyraflufen-ethyl (ISO); 2-chloro-5-(4-chloro-5-difluoromethoxy-1-methylpyrazol-3-yl)-4-fluorophenoxyacetic acid ethyl ester; [1] pyraflufen (ISO); 2-chloro-5-(4-chloro-5-difluoromethoxy-1-methylpyrazol-3-yl)-4-fluorophenoxyacetic acid [2] -[1] -[2] 129630-19-9 [1] … 314 unchanged lines … Aquatic Chronic 3 H314 H412 GHS05 Dgr H314 H412 613-259-00-5 reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate 428-790-6 72963-72-5 Acute Tox. 4 * H412 613-259-00-5 imiprothrin (ISO); reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate 428-790-6 72963-72-5 Carc. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 H302 Aquatic Chronic 1 H351 H332 H302 H371 (nervous system; oral, inhalation) H400 H410 GHS07 H410 GHS08 GHS07 GHS09 Wng H302 H410 613-260-00-0 (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolin 430-730-9 — Eye Dam. 1 Wng H351 H332 H302 H371 (nervous system; oral, inhalation) H410 inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 550 mg/kg bw M = 10 M = 10 613-260-00-0 (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolin 430-730-9 — Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H318 H400 … 553 unchanged lines … Dgr H360D H410 M = 1000 M = 1000 613-330-00-0 2-methylimidazole 211-765-7 693-98-1 Repr. 1B H360Df GHS08 Dgr H360Df 614-001-00-4 nicotine (ISO); Dgr H360Df 613-331-00-6 (2RS)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol; mefentrifluconazole - 1417782-03-6 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410 M = 1 M = 1 613-332-00-1 oxathiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone - 1003318-67-9 Aquatic Chronic 1 H410 GHS09 Wng H410 M = 1 613-333-00-7 pyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O)pyridine-2(1H)-thionato-.kappa.S]zinc 236-671-3 13463-41-7 Repr. 1B Acute Tox. 2 Acute Tox. 3 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H330 H301 H372 H318 H400 H410 GHS08 GHS06 GHS05 GHS09 Dgr H360D H330 H301 H372 H318 H410 inhalation: ATE = 0,14 mg/L (dusts or mists) oral: ATE = 221 mg/kg bw M = 1000 M = 10 613-334-00-2 flurochloridone (ISO); 3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one 262-661-3 61213-25-0 Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H360FD H302 H317 H400 H410 GHS08 GHS07 GHS09 Dgr H360FD H302 H317 H410 oral: ATE = 500 mg/kg bw M = 100 M = 100 613-335-00-8 4,5-dichloro-2-octyl-2H-isothiazol-3-one; [DCOIT] 264-843-8 64359-81-5 Acute Tox. 2 Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H330 H302 H314 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H330 H302 H314 H317 H410 EUH071 inhalation: ATE = 0,16 mg/L (dusts or mists) oral: ATE = 567 mg/kg bw Skin Irrit. 2; H315: 0,025 % ≤ C < 5 % Eye Irrit. 2; H319: 0,025 % ≤ C < 3 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100 613-336-00-3 2-methyl-1,2-benzothiazol-3(2H)-one; [MBIT] - 2527-66-4 Acute Tox. 4 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2 H312 H301 H314 H318 H317 H400 H411 GHS06 GHS05 GHS09 Dgr H312 H301 H314 H317 H410 EUH071 dermal: ATE = 1100 mg/kg bw oral: ATE = 175 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 1 614-001-00-4 nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 200-193-3 54-11-5 Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 … 823 unchanged lines … H319 GHS06 Dgr H311 H302 H319 616-014-00-0 2-butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime 202-496-6 96-29-7 Carc. 2 Acute Tox. 4 * H319 616-014-00-0 butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime 202-496-6 96-29-7 Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT SE 3 STOT SE 1 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 H351 Skin Sens. 1 H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317 GHS08 GHS06 GHS05 GHS07 Dgr H351 Dgr H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317 616-015-00-6 alachlor (ISO); H317 dermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw 616-015-00-6 alachlor (ISO); 2-chloro-2',6'-diethyl-N-(methoxymethyl)acetanilide 240-110-8 15972-60-8 Carc. 2 Acute Tox. 4 * Skin Sens. 1 … 1,035 unchanged lines … H373 GHS08 Wng H361fd H362 H373 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 H373 616-228-00-4 3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide; fluxapyroxad - 907204-31-3 Lact. Aquatic Acute 1 Aquatic Chronic 1 H362 H400 H410 GHS09 Wng H362 H410 M = 1 M = 1 616-230-00-5 N-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA] 213-103-2 924-42-5 Carc. 1B Muta. 1B STOT RE 1 H350 H340 H372 (peripheral nervous system) GHS08 Dgr H350 H340 H372 (peripheral nervous system) 616-231-00-0 5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]-1H-pyrazole-4-carboxamide; 2'-[(RS)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide; penflufen - 494793-67-8 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H400 H410 GHS08 GHS09 Wng H351 H410 M = 1 M = 1 616-232-00-6 iprovalicarb (ISO); isopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate - 140923-17-7 Carc. 2 H351 GHS08 Wng H351 616-233-00-1 silthiofam (ISO); N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide - 175217-20-6 STOT RE 2 Aquatic Chronic 2 H373 H411 GHS08 GHS09 Wng H373 H411 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 H225 H341 GHS02 GHS08 … 45 unchanged lines … Dgr H242 H302 H314 H410 STOT SE 3; H335: C ≥ 5 % 617-006-00-X bis(α, α-dimethylbenzyl) peroxide 201-279-3 80-43-3 Org. Perox. F H410 STOT SE 3; H335: C ≥ 5 % 617-006-00-X bis(α,α-dimethylbenzyl) peroxide 201-279-3 80-43-3 Org. Perox. F Repr. 1B Skin Irrit. 2 Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 H242 H360D H315 H319 H315 H411 GHS02 GHS08 GHS07 GHS09 Wng H242 Dgr H242 H360D H315 H319 H315 H411 617-007-00-5 tert-butyl α, α-dimethylbenzyl peroxide 222-389-8 3457-61-2 Org. Perox. E Skin Irrit. 2 Aquatic Chronic 2 H242 … 5,136 unchanged lines … STOT RE 1 H360FD H372 (immune system) GHS08 Dgr H360FD H372 (immune system) Table 3.2 H372 (immune system) 650-057-00-6 Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide] 283-644-7 84696-25-3 Aquatic Chronic 3 H412 H412 Table 3.2 The list of harmonised classification and labelling of hazardous substances from Annex I to Directive 67/548/EEC Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes 001-001-00-9 hydrogen 215-605-7 1333-74-0 F+; R12 F+ … 19,751 unchanged lines … S: 61 650-055-00-5 silver sodium zirconium hydrogenphosphate 422-570-3 155925-27-2 N; R50-53 N R: 50/53 S: 60-61